Compare Novo Nordisk A/S (NVO) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Sea Limited — how do they compare? Novo Nordisk A/S trades at $45.07 (market cap $198.57B), while Sea Limited trades at $106.88 (market cap $66.58B). The key difference: Novo Nordisk A/S is far larger — about 3× Sea Limited's market cap, and Novo Nordisk A/S pays a 4.03% dividend while Sea Limited pays none. Which is the better fit depends on your goals.
| NVO | SE | |
|---|---|---|
Market Cap | $198.57B | $66.58B |
Sector | Health | Media |
52-Week High | $63.98 | $196.50 |
52-Week Low | $35.29 | $78.16 |
Enterprise Value | $213.37B | $61.61B |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Sea Limited (SE) trades at $113.33, up 1.11% with bullish technical signals and strong analyst support. The company shows robust revenue growth from $16.8B in 2024 to $22.9B in 2025, with net income reaching $1.58B. Recent earnings beat expectations in Q1 and Q2 2026, while operating cash flow improved significantly to $5.02B in 2025. Technical indicators show bullish moving averages with support at $111 and resistance at $115.
SE presents a compelling growth story with expanding profitability and positive cash flow generation. However, elevated valuation multiples (P/E 43.76) and insider selling activity warrant caution. The consensus price target of $143.67 suggests 27% upside potential, but investors should monitor competitive pressures in Southeast Asian markets and execution risks as the company scales.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
